Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027497 (
nausea
)
23,468
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Concentrations of the antidiuretic hormone,
arginine vasopressin
, were measured in 28 patients with severe hyperglycemia to determine if abnormalities in hormonal regulation of water excretion could contribute to the extreme dehydration of uncontrolled diabetes mellitus. Vasopressin levels were markedly elevated in both nonketotic and ketotic patients, indicating that vasopressin deficiency plays no role in the polyuria that accompanies hyperglycemia. Instead, the observed increases in vasopressin represent an ineffective effort to conserve water in the face of an overwhelming solute diuresis caused by the glucosuria. The reasons for such marked elevations in plasma vasopressin in these diabetic patients are multifactorial. Both groups of diabetic patients had evidence of hypovolemia, which was sufficient in magnitude to stimulate vasopressin release. Furthermore,
nausea
provided an independent stimulus to vasopressin secretion in many patients. Osmotic stimulation might have resulted from the large fraction of unidentified plasma solutes, but this factor alone was not sufficient to explain the markedly increased concentrations of vasopressin. Whether such elevations in vasopressin could have metabolic and/or hemodynamic effects in uncrontrolled diabetes remains to be established.
...
PMID:Plasma vasopressin in uncontrolled diabetes mellitus. 10 67
Experimental evidence indicates that
arginine vasopressin
(
AVP
) contributes to the release of ACTH under certain conditions. The present study investigates the role of vasopressin as a secretagogue of ACTH during cigarette smoking or nicotine infusion with additional injection of corticotropin releasing hormone (CRH) and using the specific
AVP
antagonist d(CH2)5Tyr(Me)-
AVP
. We first tested the effect of the
AVP
antagonist (10 micrograms/kg body weight i.v.) on ACTH and cortisol release following cigarette smoking in 15 healthy young male smokers. Smoking led to marked increments in plasma nicotine and to a small rise in plasma ACTH and cortisol. Mean plasma ACTH and cortisol levels were at no time significantly altered by the antagonist. This might be due to a slight agonistic effect of the
AVP
antagonist, to high interindividual variability of the ACTH and cortisol responses after smoking or to a negligible role of
AVP
in smoking-induced ACTH release. In a second study we performed the following tests in six healthy male non-smokers: (1) nicotine infusion (1.0 micrograms/kg body weight per min); (2) CRH i.v. (100 micrograms); (3)
AVP
antagonist i.v. (5 micrograms/kg); (4) nicotine infusion plus CRH i.v.; (5) nicotine infusion plus
AVP
antagonist i.v.; (6) nicotine infusion plus CRH and
AVP
antagonist i.v.; and (7) sham infusion. Nicotine infusion led to greater increments of
AVP
, ACTH and cortisol than smoking without causing
nausea
. Peak nicotine levels after nicotine infusion were lower than after smoking. The
AVP
antagonist in the reduced dosage given alone had no effect on hormone levels. However, it slightly attenuated the effect of nicotine on ACTH and cortisol (P less than 0.05, ANOVA).(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:The role of vasopressin in the nicotine-induced stimulation of ACTH and cortisol in men. 132 53
This experimentation partially defines, for the first time, the response of beta-endorphin (ENDO) in man during tests designed to elicit
nausea
and motion sickness. These responses are similar to those associated with
arginine vasopressin
(
AVP
) and adrenocorticotropin (ACTH) to the extent that all hormones rise in response to motion sickness (p < 0.003). Repeated exposure diminished motion-induced release of ENDO (p < 0.005) and
AVP
(p < 0.004) despite a three-fold increase in resistance to motion stimuli. Higher post-stress levels of
AVP
(p < 0.04) and ACTH (p < 0.02) were correlated with greater resistance to motion sickness. These data support the hypothesis that release of
AVP
is a significant link between stressful motion and motion-induced
nausea
and other autonomic system changes. Further, resistant individuals apparently can tolerate higher peripheral levels of
AVP
before
nausea
results. Peripheral release of ENDO and ACTH may follow release of
AVP
; however, given the extensive and complex functional interactions that exist between
AVP
and the opiate systems, it is not yet possible to define a clear role for ENDO in the etiology of motion sickness.
...
PMID:beta-Endorphin and arginine vasopressin following stressful sensory stimuli in man. 133 70
Human urine samples, purified on octadecasilyl-silica cartridges, contained immunoreactive angiotensin I, II,
arginine vasopressin
and oxytocin. The daily excretion of these peptides in healthy volunteers was 190.00 +/- 38.43 (n = 12), 17.48 +/- 3.09 (n = 12), 63.43 +/- 14.84 (n = 8) and 13.52 +/- 1.42 (n = 7) pmol/24 hr, respectively (mean +/- s.e.m.). Patients with a history of anaphylactoid reactions to drugs or food additives showed clinical symptoms such as urticaria, flush,
nausea
, dizziness and hypotension after oral provocation with cyanocobalamine, propyphenazone, acetylsalicylic acid and sodium benzoate. In five of the seven patients, angiotensin I and II were increased several fold in the urine fractions after symptoms were reported. The average increase in the urine concentration of both peptides was fourfold and 5.5-fold. In three out of five patients, the mean excretion of
arginine vasopressin
and oxytocin immunoreactive material was also elevated by a factor of 5.7 and 4.4, respectively. Oral provocation with a placebo failed to elicit anaphylactoid symptoms or an increase in the urine levels of angiotensin I or angiotensin II. Angiotensin I and angiotensin II-like immunoreactivity could be characterized on HPLC as Ile5-angiotensin I, Ile5-angiotensin II and angiotensin II metabolites. HPLC characterization of immunoreactive
arginine vasopressin
and oxytocin in two different gradient systems showed retention times different than the retention times of the corresponding synthetic standard peptides indicating that both peptides are not authentic AVP and OXT. These results suggest that angiotensin I and angiotensin II may be involved in the clinical events observed during some forms of anaphylactoid reactions.
...
PMID:Urinary excretion of angiotensin I, II, arginine vasopressin and oxytocin in patients with anaphylactoid reactions. 142 42
Nausea
in response to an appetizing food stimulus was assessed in bulimic women and healthy control subjects.
Nausea
was assessed via subjects' self-report and changes in levels of plasma
arginine vasopressin
(
AVP
), a hormonal correlate of
nausea
. Converging evidence was obtained indicating that bulimic women experienced
nausea
in response to the sight, smell, or taste of the palatable food stimulus. The possibility that the observed
nausea
is a learned response that may contribute to the bulimic binge/purge pattern is discussed.
...
PMID:Nausea in bulimic women in response to a palatable food. 234 13
To assess central nervous system cholinergic neuroendocrine regulation in Alzheimer's disease (AD), we measured plasma
arginine vasopressin
, beta-endorphin, and epinephrine responses to a cholinergic challenge elicited by intravenous administration of the acetylcholinesterase inhibitor physostigmine (0.0125 mg/kg) in male patients with AD (n = 12) and compared their responses with those of age-matched normal control subjects (n = 12). Physostigmine promptly increased plasma
arginine vasopressin
(tenfold), beta-endorphin (twofold to threefold) and epinephrine (threefold) levels in elderly control subjects. In contrast, patients with AD showed attenuated responses to physostigmine. When controls and patients with AD who experienced
nausea
(n = 2 and n = 6, respectively) were excluded, the
arginine vasopressin
, beta-endorphin, and epinephrine responses of patients with AD were significantly less than those of control subjects. These data suggest that the central nervous system cholinergic deterioration of AD results in decreased responsiveness of neuroendocrine systems that are regulated by central cholinergic mechanisms.
...
PMID:Neuroendocrine responses to physostigmine in Alzheimer's disease. 252 15
Apomorphine, a centrally-acting emetic, was administered subcutaneously (50 micrograms/kg) to nine normal subjects (four male, five female; aged 22-36 years) and four patients with idiopathic diabetes insipidus (DI) (one male, three female; aged 24-49 years). In the normal subjects this stimulus caused
nausea
(and vomiting in seven of nine) with a latency of 9.5 +/- 0.9 min which was followed by a large increase in plasma
arginine vasopressin
(
AVP
) concentration (from 0.9 +/- 0.2 pmol/l to 249 +/- 104 pmol/l at 15 min after the onset of symptoms; mean +/- SEM, P less than 0.01). There was a small but significant increase in plasma oxytocin (OXT) concentration (from 1.6 +/- 0.4 pmol/l to 6.2 +/- 3.4 pmol/l; P less than 0.05). Mean arterial pressure (MAP) fell slightly (from 87 +/- 1.9 mm Hg to 71 +/- 4.4 mm Hg; P less than 0.05) 15 min after the onset of
nausea
; there was no change in blood haematocrit or plasma osmolality and sodium concentration. In the DI patients apomorphine produced
nausea
(with vomiting in three of four) with a latency of 10.0 +/- 1.4 min but failed to cause an increase in either plasma
AVP
or OXT. In the DI patients the fall in MAP did not reach statistical significance (83 +/- 4 mm Hg to 71 +/- 11 mm Hg); there was also no change in haematocrit, osmolality or sodium concentration. Ipecacuanha, an emetic with both peripheral and central actions, was administered orally to seven normal subjects (three male, four female; aged 22-36 years) six of whom also underwent apomorphine tests.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Responses of plasma oxytocin and arginine vasopressin to nausea induced by apomorphine and ipecacuanha. 290 23
Exogenous administration of cholecystokinin octapeptide (CCK) is known to decrease food intake and slow gastric emptying in humans and animals. Recent studies have shown that CCK stimulates neurohypophyseal secretion of oxytocin (OT) in rats and
arginine vasopressin
(
AVP
) in monkeys, and that gastric distention also stimulates OT release in rats. We therefore studied
AVP
and OT secretion in 14 normal subjects in response to meal-induced gastric distention and administration of CCK, both separately and in combination, to assess whether these stimuli similarly activated central neurohypophyseal pathways in humans. Neither plasma
AVP
nor OT concentrations increased after gastric distention produced by ingestion of a large meal. However, a dose-related increase in plasma
AVP
, but not OT levels, occurred after CCK administration, the threshold CCK dose being 0.05 micrograms/kg body weight. The
AVP
secretion in response to CCK administration was significantly correlated with subjective aversive symptoms quantified by use of a numeric scale (r = 0.61, P less than 0.001). In 12 of the 14 subjects plasma
AVP
levels increased in association with symptoms of epigastric pressure and discomfort before the onset of overt
nausea
or emesis. The combination of CCK and meal-induced gastric distention did not stimulate increases in plasma
AVP
levels in excess of those produced by CCK administration alone. The results demonstrate that
AVP
secretion resulting from emetic center activation often is a graded response that can begin in association with milder degrees of visceral discomfort before symptoms of overt
nausea
or emesis. In addition, the stimulation of
AVP
secretion by CCK administration, but not by meal-induced gastric distention in association with physiological satiety, suggests that some component of the anorectic effects of exogenous CCK in man likely results from activation of brainstem emetic centers.
...
PMID:Neurohypophyseal secretion in response to cholecystokinin but not meal-induced gastric distention in humans. 292 13
Concentrations of plasma
arginine vasopressin
(
AVP
) were studied in patients receiving chemotherapy. Of the 18 patients studied, nine experienced nausea and vomiting and the remaining nine were nonvomiters who suffered at worst mild
nausea
. Plasma
AVP
in the non-vomiting group remained within the normal range (0.5-1.5 pmol 1(-1] throughout the sampling period. However, patients who vomited showed (with one exception) substantial rises in
AVP
ranging from 4 to 129-fold. Plasma
AVP
concentrations were outside the normal range in vomiters and were higher than in non-vomiting patients at 3 h (P less than 0.05) and 5h (P less than 0.01) after chemotherapy. One patient was sampled during consecutive treatment courses, once as a vomiter and once as a non-vomiter; results demonstrated a 16-fold rise in
AVP
as a vomiter and no rise as a non-vomiter. Significant changes in plasma
AVP
levels were also observed in patients who suffered moderate or severe
nausea
compared to those who had mild or no
nausea
(P less than 0.05). Plasma
AVP
may prove to be a good objective marker for
nausea
in future anti-emetic trials.
...
PMID:Arginine vasopressin--a mediator of chemotherapy induced emesis? 293 Jul 16
The plasma concentration of
arginine vasopressin
(
AVP
) is increased in diabetic ketoacidosis (DKA) in man and the rat. Although haemodynamic changes and
nausea
/emesis may account for the increased secretion of
AVP
in severe human DKA, they appear not to be responsible in moderate DKA. Streptozotocin-treated rats were studied to investigate other factors possibly involved in the secretion of
AVP
in DKA. Wistar rats were injected i.p. with streptozotocin (150 mg/kg body weight). Diabetic rats were maintained on 3-4 units protamine-zinc insulin (PZI)/day for 11 days, after which PZI was withdrawn for 3 days in half the rats. The plasma concentration of
AVP
was greater in rats with DKA than in normal controls (mean 11.4 pmol/l compared with 1.6 pmol/l; P less than 0.05). Rats with DKA had higher plasma osmolality and concentrations of blood glucose, beta-hydroxybutyrate and acetoacetate, but lower plasma carbon dioxide content than diabetic and normal controls (P less than 0.05). There were no differences in plasma levels of sodium, urea or haematocrit between rats with DKA and controls. In a separate study involving the same procedures, daily systolic blood pressure was measured using a tail cuff to occlude arterial inflow to the tail, and subsequent detection of the cuff pressure at which the first arterial pulsation appeared. No significant differences were detected between normal and diabetic rats and rats with DKA. Exponential relationships between plasma osmolality and plasma
AVP
(correlation coefficient, r = + 0.75; P less than 0.01), and plasma ketone bodies and plasma
AVP
(r = +0.60; P less than 0.05) were obtained.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Possible mechanisms responsible for the rise in plasma vasopressin associated with diabetic ketoacidosis in the rat. 312 19
1
2
3
Next >>